ConductScience.org, home

Comparison · NCT03089983-3513e441

Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Adherence

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Adherence. Trial comparisons, record NCT03089983-3513e441. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03089983-3513e441

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05920.03150.109wilson
Risk in group 20.7650.6920.825wilson
Risk difference, group 1 minus group 2-0.705-0.772-0.617newcombe hybrid score
Risk ratio, group 1 over group 20.07740.04080.147log
Odds ratio, group 1 over group 20.01940.008960.0418log
Number needed to treat, for one fewer participant with the outcome on Standard Isoniazid (INH) for 26 Weeks than on Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks1.421.31.62from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Standard Isoniazid (INH) for 26 WeeksParticipants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison as TB preventative treatment9152OG000
Group 2Short-course Isoniazid + Rifapentine (INH + RIF) for 12 WeeksParticipants will be randomized to receive INH + RIF as TB preventative treatment for 12 weeks while in prison.117153OG001

Outcome

Type
SECONDARY
Title
TB Treatment Adherence
Description
TB treatment adherence in prison will be verified using medical records. All TB treatment in prison will be administered under directly observed therapy (DOTs), and treatment administration will be recorded in the participant's prison medical record. Data presented here is the number of participants that adhered to TB treatment of those that initiated treatment.
Time frame
monthly for up to 6 months
Population

Source ClinicalTrials.gov

Trial

Title
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
NCT number
NCT03089983
Phases
NA
Conditions
Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis, Hepatitis
Interventions
Isoniazid, Rifapentine
Lead sponsor
Yale University
Results first posted
2026-02-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03089983-3513e441